Edward J Benz

Edward J. Benz, Jr, MD, is the President and Chief Executive Officer Emeritus of the Dana-Farber Cancer Institute and the Richard and Susan Smith Distinguished Professor of Medicine, Professor of Pediatrics, Professor of Genetics, and Faculty Dean for Oncology Emeritus at Harvard Medical School. Previously, Dr. Benz served as President and Chief Executive Officer of the Dana-Farber Cancer Institute, Prior to joining Dana-Farber, Dr. Benz was Chairperson of the Department of Medicine, Sir William Osler Professor of Medicine, Professor of Molecular Biology and Genetics, and Physician-in-Chief at the Johns Hopkins University School of Medicine. Dr. Benz currently serves on the Boards of Directors of Deciphers Pharmaceuticals, Candel Therapeutics (formerly known as Advantagene) and F-Star Therapeutics, and previously on the Boards of Knowledge to Practice, Inc., and Xenetic, Inc. His non-profit governance activities include the Boards of Trrustees of Rockefellar University, the Mount Desert Island Hospital, The MDI Biolabs, and Dana-Farber.

Dr. Benz holds a MD magna cum laude from Harvard Medical School, a MA Ad Privatim degree from Yale University and an AB degree cum laude from Princeton University.